603087 甘李药业
已收盘 04-30 15:00:00
资讯
新帖
简况
长城国瑞证券：给予甘李药业买入评级
证券之星 · 12:39
长城国瑞证券：给予甘李药业买入评级
甘李药业（603087）2026年一季报简析：净利润同比下降38.29%
证券之星 · 04-24
甘李药业（603087）2026年一季报简析：净利润同比下降38.29%
4月23日甘李药业跌9.44%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 04-23
4月23日甘李药业跌9.44%，招商国证生物医药指数(LOF)C基金重仓该股
国金证券：给予甘李药业买入评级
证券之星 · 04-23
国金证券：给予甘李药业买入评级
甘李药业最新公告：2025年净利润同比增长86.05%拟10派10元
证券之星 · 04-22
甘李药业最新公告：2025年净利润同比增长86.05%拟10派10元
甘李药业最新公告：注射用GLR1059获药物临床试验批准
证券之星 · 04-21
甘李药业最新公告：注射用GLR1059获药物临床试验批准
甘李药业（603087）披露获得GLR1062注射液临床试验批准通知书，4月16日股价上涨0.02%
证券之星 · 04-16
甘李药业（603087）披露获得GLR1062注射液临床试验批准通知书，4月16日股价上涨0.02%
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
21世纪经济报道 · 04-15
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
甘李药业最新公告：GZR33注射液Ⅲ期临床试验完成首例受试者给药
证券之星 · 04-14
甘李药业最新公告：GZR33注射液Ⅲ期临床试验完成首例受试者给药
每周股票复盘：甘李药业（603087）全资子公司获西格列汀二甲双胍片批件
证券之星 · 04-12
每周股票复盘：甘李药业（603087）全资子公司获西格列汀二甲双胍片批件
甘李药业与多方合作 推进Bofanglutide注射液在韩临床开发
美股速递 · 04-09
甘李药业与多方合作 推进Bofanglutide注射液在韩临床开发
甘李药业（603087）披露全资子公司获得药品注册批件公告，4月7日股价下跌0.4%
证券之星 · 04-07
甘李药业（603087）披露全资子公司获得药品注册批件公告，4月7日股价下跌0.4%
甘李药业最新公告：全资子公司获得西格列汀二甲双胍片（Ⅱ）药品注册批件
证券之星 · 04-07
甘李药业最新公告：全资子公司获得西格列汀二甲双胍片（Ⅱ）药品注册批件
每周股票复盘：甘李药业（603087）GLR2037片Ⅰ期临床完成首例给药
证券之星 · 04-05
每周股票复盘：甘李药业（603087）GLR2037片Ⅰ期临床完成首例给药
甘李药业(603087.SH)：GLR2037片Ⅰ期临床试验完成首例受试者给药
智通财经 · 04-03
甘李药业(603087.SH)：GLR2037片Ⅰ期临床试验完成首例受试者给药
甘李药业(603087.SH)子公司通过巴西国家卫生监督局GMP认证
智通财经 · 04-02
甘李药业(603087.SH)子公司通过巴西国家卫生监督局GMP认证
甘李药业GZR4注射液26周疗效显著：降糖效果优于来得时与德谷胰岛素
美股速递 · 03-31
甘李药业GZR4注射液26周疗效显著：降糖效果优于来得时与德谷胰岛素
甘李药业：一周一次Gzr4相比每日胰岛素，年注射次数减少超85%
美股速递 · 03-31
甘李药业：一周一次Gzr4相比每日胰岛素，年注射次数减少超85%
甘李药业周制剂GZR4安全性表现优异，无严重低血糖事件报告
美股速递 · 03-31
甘李药业周制剂GZR4安全性表现优异，无严重低血糖事件报告
甘李药业周制剂基础胰岛素GZR4注射液两项关键III期临床试验SUPER-1与SUPER-2均达到主要终点
美股速递 · 03-31
甘李药业周制剂基础胰岛素GZR4注射液两项关键III期临床试验SUPER-1与SUPER-2均达到主要终点
加载更多
公司概况
公司名称：
甘李药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-29
主营业务：
甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。
发行价格：
63.32
{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"甘李药业","latestPrice":58.85,"timestamp":1777532401000,"preClose":59.81,"halted":0,"volume":6081580,"delay":0,"changeRate":-0.0161,"floatShares":558000000,"shares":597000000,"eps":1.7147,"marketStatus":"已收盘","change":-0.96,"latestTime":"04-30 15:00:00","open":59.91,"high":59.97,"low":58.7,"amount":360000000,"amplitude":0.0212,"askPrice":58.85,"askSize":96,"bidPrice":58.84,"bidSize":15,"shortable":0,"etf":0,"ttmEps":1.7147,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":59.81,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":65.79,"lowLimit":53.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597304969,"isCdr":false,"pbRate":2.97,"roa":"--","peRate":34.320872,"roe":"1.64%","epsLYR":1.93,"committee":0.275591,"marketValue":35151000000,"turnoverRate":0.0109,"status":1,"floatMarketCap":32830000000},"requestUrl":"/m/hq/s/603087","defaultTab":"news","newsList":[{"id":"2631350588","title":"长城国瑞证券：给予甘李药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2631350588","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631350588?lang=zh_cn&edition=full","pubTime":"2026-04-30 12:39","pubTimestamp":1777523947,"startTime":"0","endTime":"0","summary":"长城国瑞证券有限公司胡晨曦近期对甘李药业进行研究并发布了研究报告《2025年业绩高增，全球化与创新双轮驱动》，给予甘李药业买入评级。考虑公司胰岛素集采后销量持续放量，叠加海外业务增长潜力充足、博凡格鲁肽注射液等在研管线推进顺利，成长动能较强，我们维持其“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000042897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629840399","title":"甘李药业（603087）2026年一季报简析：净利润同比下降38.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629840399","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629840399?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:16","pubTimestamp":1777040164,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期甘李药业发布2026年一季报。根据财报显示，甘李药业净利润同比下降38.29%。截至本报告期末，公司营业总收入8.78亿元，同比下降10.84%，归母净利润1.92亿元，同比下降38.29%。去年的净利率为28.22%，算上全部成本后，公司产品或服务的附加值高。持有甘李药业最多的基金为招商国证生物医药指数C，目前规模为15.1亿元，最新净值0.3911，较上一交易日下跌1.73%，近一年上涨11.71%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400064793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629886570","title":"4月23日甘李药业跌9.44%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629886570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629886570?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:24","pubTimestamp":1776932643,"startTime":"0","endTime":"0","summary":"证券之星消息，4月23日甘李药业跌9.44%，收盘报59.48元，换手率3.86%，成交量21.51万手，成交额13.09亿元。重仓甘李药业的前十大公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共42家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.1亿元，最新净值0.398，较上一交易日上涨0.45%，近一年上涨13.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300044541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087","399441","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629050060","title":"国金证券：给予甘李药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2629050060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629050060?lang=zh_cn&edition=full","pubTime":"2026-04-23 11:57","pubTimestamp":1776916648,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,马居东近期对甘李药业进行研究并发布了研究报告《25年业绩高增，研发及出海加速》，给予甘李药业买入评级。其中第四代基础胰岛素GZR4注射液在中国开展用于治疗2型糖尿病的三项III期临床研究均于25年2月完成首例给药，与诺和诺德已上市胰岛素周制剂依柯胰岛素开展的头对头对比的III期临床研究于25年10月完成首例给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300032985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629861010","title":"甘李药业最新公告：2025年净利润同比增长86.05%拟10派10元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629861010","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629861010?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:39","pubTimestamp":1776854391,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)发布2025年年度报告，实现营业收入40.52亿元，同比增长33.06%；归属于上市公司股东的净利润为11.44亿元，同比增长86.05%。公司拟向全体股东每10股派发现金股利10元(含税)。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200045172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629087199","title":"甘李药业最新公告：注射用GLR1059获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2629087199","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629087199?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:10","pubTimestamp":1776766233,"startTime":"0","endTime":"0","summary":"甘李药业公告称，公司近日收到国家药监局下发的关于在研药品注射用GLR1059的《药物临床试验批准通知书》，同意本品单药在晚期实体瘤中开展临床试验。注射用GLR1059是公司自主研发的靶向Nectin-4的抗体偶联药物，适应症为晚期实体瘤。截至2025年9月30日，该项目累计投入研发费用4671.03万元。该产品下一阶段将按规定开展临床试验，待成功后按法定程序申报生产。由于医药研发具有高风险、长周期等特点，存在不确定性，敬请投资者注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100041051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627295195","title":"甘李药业（603087）披露获得GLR1062注射液临床试验批准通知书，4月16日股价上涨0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627295195","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627295195?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:17","pubTimestamp":1776331045,"startTime":"0","endTime":"0","summary":"截至2026年4月16日收盘，甘李药业报收于65.97元，较前一交易日上涨0.02%，最新总市值为394.04亿元。甘李药业股份有限公司于近日披露《关于获得〈药物临床试验批准通知书〉的公告》。公告显示，公司收到国家药品监督管理局下发的《药物临床试验批准通知书》，同意公司GLR1062注射液开展治疗成人的新生血管（湿性）年龄相关性黄斑变性的临床试验。截至2025年9月30日，该项目累计研发投入4,996.72万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600031195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BKVL7J92.USD","REGN","BK4599","NVO","IE00BZ1G4Q59.USD","BK4585","600513","300558","301087","LU0154236417.USD","600196","NVOH","LU1093756168.USD","BK4007","BK4588","LU1093756325.SGD","BK4532","002437","603087","NVOX","688177","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627419730","title":"甘李药业最新公告：GZR33注射液Ⅲ期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2627419730","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627419730?lang=zh_cn&edition=full","pubTime":"2026-04-14 17:04","pubTimestamp":1776157442,"startTime":"0","endTime":"0","summary":"甘李药业公告称，公司全资子公司自主研发的GZR33注射液正在中国开展适应症为2型糖尿病的Ⅲ期临床试验，于近日成功完成首例受试者给药。GZR33注射液为公司自主研发的长效基础胰岛素日制剂，相较已上市同类产品德谷胰岛素，具有血药浓度更平稳、药效持续时间更长等特点。该产品于2026年3月获国家药监局同意开展Ⅲ期临床试验反馈。截至2025年9月30日，公司在该项目中累计投入研发费用8426.35万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400027127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626224621","title":"每周股票复盘：甘李药业（603087）全资子公司获西格列汀二甲双胍片批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2626224621","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626224621?lang=zh_cn&edition=full","pubTime":"2026-04-12 02:08","pubTimestamp":1775930891,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，甘李药业报收于64.12元，较上周的63.15元上涨1.54%。本周，甘李药业4月9日盘中最高价报65.13元。本周关注点公司公告汇总：全资子公司获得西格列汀二甲双胍片（Ⅱ）药品注册批件。公司公告汇总关于全资子公司获得药品注册批件的公告甘李药业全资子公司甘李药业山东有限公司近日收到国家药监局下发的西格列汀二甲双胍片（Ⅱ）药品注册批件，注册分类为化学药品4类，上市许可持有人为甘李药业山东有限公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109615986","title":"甘李药业与多方合作 推进Bofanglutide注射液在韩临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1109615986","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109615986?lang=zh_cn&edition=full","pubTime":"2026-04-09 21:14","pubTimestamp":1775740498,"startTime":"0","endTime":"0","summary":"甘李药业宣布，将与多方携手合作，共同推进Bofanglutide注射液在韩国的临床开发工作。此次合作旨在加速该创新药物在韩国市场的研发进程，为当地患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625593009","title":"甘李药业（603087）披露全资子公司获得药品注册批件公告，4月7日股价下跌0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625593009","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625593009?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:16","pubTimestamp":1775571383,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，甘李药业报收于62.9元，较前一交易日下跌0.4%，最新总市值为375.7亿元。该股当日开盘63.15元，最高64.21元，最低62.78元，成交额达2.97亿元，换手率为0.84%。甘李药业近日披露公告，其全资子公司甘李药业山东有限公司收到国家药监局下发的西格列汀二甲双胍片（Ⅱ）药品注册批件，注册分类为化学药品4类，上市许可持有人为甘李药业山东有限公司。截至2025年9月30日，该项目累计研发投入929.35万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700033419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625362789","title":"甘李药业最新公告：全资子公司获得西格列汀二甲双胍片（Ⅱ）药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2625362789","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625362789?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:21","pubTimestamp":1775553703,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)公告称，公司全资子公司甘李药业山东有限公司于近日收到国家药监局下发的西格列汀二甲双胍片(Ⅱ)产品注册批件。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625382616","title":"每周股票复盘：甘李药业（603087）GLR2037片Ⅰ期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2625382616","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625382616?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:47","pubTimestamp":1775324829,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，甘李药业报收于63.15元，较上周的61.72元上涨2.32%。本周，甘李药业4月1日盘中最高价报65.5元。甘李药业当前最新总市值377.2亿元，在生物制品板块市值排名6/51，在两市A股市值排名511/5193。甘李药业自主研发的GLR2037片Ⅰ期临床试验完成首例受试者给药。2026年3月获国家药监局临床试验批准，通知书编号为2026LP00526、2026LP00527。截至2025年9月30日，项目累计研发投入5,805.47万元。临床试验进展可能受多种因素影响，公司将按规定推进并披露后续情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624653165","title":"甘李药业(603087.SH)：GLR2037片Ⅰ期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2624653165","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624653165?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:39","pubTimestamp":1775201942,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)公告，公司自主研发的GLR2037片正在中国开展Ⅰ期临床试验，于近日成功完成首例受试者给药。GLR2037片是甘李药业自主研发的雄激素受体-蛋白降解靶向嵌合体(ARPROTAC)1类化学新药，本次临床试验拟开展的适应症为晚期前列腺癌","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"甘李药业(603087.SH)：GLR2037片Ⅰ期临床试验完成首例受试者给药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624058495","title":"甘李药业(603087.SH)子公司通过巴西国家卫生监督局GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2624058495","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624058495?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:21","pubTimestamp":1775128878,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，近日，公司子公司甘李药业巴西贸易与医药进口有限责任公司(简称“甘李巴西”)收到巴西国家卫生监督局(简称“巴西ANVISA”)核准签发的药品生产质量管理规范(GMP)认证证书。认证范围：门冬胰岛素原料药、赖脯胰岛素原料药。本次顺利通过巴西ANVISA的GMP认证，为公司产品赖脯胰岛素和门冬胰岛素进入巴西市场奠定了坚实基础，对公司国际化战略推进具有积极意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603087","159100","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143850390","title":"甘李药业GZR4注射液26周疗效显著：降糖效果优于来得时与德谷胰岛素","url":"https://stock-news.laohu8.com/highlight/detail?id=1143850390","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143850390?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:39","pubTimestamp":1774964378,"startTime":"0","endTime":"0","summary":"在第26周的治疗周期后，甘李药业研发的GZR4注射液展现出卓越的降糖能力，其降低糖化血红蛋白（HbA1c）的效果明显优于对照药物来得时（Lantus）和德谷胰岛素（Tresiba）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164271814","title":"甘李药业：一周一次Gzr4相比每日胰岛素，年注射次数减少超85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164271814","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164271814?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:39","pubTimestamp":1774964356,"startTime":"0","endTime":"0","summary":"甘李药业最新研发的Gzr4胰岛素产品，凭借其一周一次的给药方案，展现出显著优势。与传统的每日一次胰岛素相比，该药物可将患者每年的注射频率大幅降低超过85%。这一突破不仅极大提升了用药便利性，也为糖尿病患者提供了全新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188766351","title":"甘李药业周制剂GZR4安全性表现优异，无严重低血糖事件报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1188766351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188766351?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:39","pubTimestamp":1774964352,"startTime":"0","endTime":"0","summary":"甘李药业研发的每周一次给药制剂GZR4在临床试验中展现出良好的安全性特征，研究期间未观察到严重低血糖事件的发生。该结果进一步验证了此类长效制剂在血糖控制方面的潜在优势，为糖尿病患者提供了更便捷、安全的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106815675","title":"甘李药业周制剂基础胰岛素GZR4注射液两项关键III期临床试验SUPER-1与SUPER-2均达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1106815675","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106815675?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:37","pubTimestamp":1774964235,"startTime":"0","endTime":"0","summary":"甘李药业宣布，其研发的每周一次基础胰岛素GZR4注射液，在两项关键性III期临床试验——SUPER-1与SUPER-2中，均成功达到了预设的主要研究终点。这一积极结果标志着该创新疗法在临床开发进程中取得了重大进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777562349986,"stockEarnings":[{"period":"1week","weight":-0.0894},{"period":"1month","weight":-0.0398},{"period":"3month","weight":-0.1172},{"period":"6month","weight":-0.1202},{"period":"1year","weight":0.2549},{"period":"ytd","weight":-0.1213}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"81965人(较上一季度减少5.45%)","perCapita":"6806股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59730万元","survey":" 甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"甘李药业,603087,甘李药业股票,甘李药业股票老虎,甘李药业股票老虎国际,甘李药业行情,甘李药业股票行情,甘李药业股价,甘李药业股市,甘李药业股票价格,甘李药业股票交易,甘李药业股票购买,甘李药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}